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OBJECTIVES: Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene
polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association
with IL28 might increase the power to predict sustained virologic response. Our aims were to evaluate the
association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene
polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated
with pegylated-interferon plus ribavirin.
METHOD: Myxovirus resistance protein, osteopontin, suppressor of cytokine signaling 3 and IL28B
polymorphisms were analyzed by PCR-restriction fragment length polymorphism, direct sequencing and real-
time PCR. Ancestry was determined using genetic markers.
RESULTS: We analyzed 181 individuals, including 52 who were sustained virologic responders. The protective
genotype frequencies among the sustained virologic response group were as follows: the G/G suppressor of
cytokine signaling 3 (rs4969170) (62.2%); T/T osteopontin (rs2853744) (60%); T/T osteopontin (rs11730582)
(64.3%); and the G/T myxovirus resistance protein (rs2071430) genotype (54%). The patients who had $3 of the
protective genotypes from the myxovirus resistance protein, the suppressor of cytokine signaling 3 and
osteopontin had a greater than 90% probability of achieving a sustained response (p,0.0001). The C/C IL28B
genotype was present in 58.8% of the subjects in this group. The sustained virological response rates increased
to 85.7% and 91.7% by analyzing C/C IL28B with the T/T osteopontin genotype at rs11730582 and the G/G
suppressor of cytokine signaling 3 genotype, respectively. Genetic ancestry analysis revealed an admixed
population.
CONCLUSION: Hepatitis C genotype 1 patients who were responders to interferon-based therapy had a high
frequency of multiple protective polymorphisms in the myxovirus resistance protein, osteopontin and
suppressor of cytokine signaling 3 genes. The combined analysis of the suppressor of cytokine signaling 3
and IL28B genotypes more effectively predicted sustained virologic response than IL28B analysis alone.
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& INTRODUCTION
Genetic and biological host factors such as the human leukocyte
antigen, ancestry, cytokine polymorphisms, gender, liver fibrosis
and insulin resistance are implicated in the effectiveness of
interferon (IFN)-a therapy in chronic hepatitis C (1,2).
The interferon system is a crucial component of the
natural immune response to infectious agents. Type I
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interferon induces numerous antiviral proteins, including
the myxovirus resistance (MxA) protein, 2-5 oligoadeny-
late synthetase 1 and double-stranded RNA-dependent
protein kinase. The MxA protein has selective activity
against a number of viruses, and its levels are higher in
chronic hepatitis C virus (HCV) patients during inter-
feron treatment; the single nucleotide polymorphisms
(SNPs) in the promoter region of MxA appear to be
associated with the response of HCV-infected patients to
interferon (3,4).
Osteopontin (OPN) is an extracellular matrix protein
expressed in activated Kupffer and stellate cells that
contributes to the migration of macrophages into the
necrotic areas of the injured liver. OPN is an essential
cytokine in initiating the Th1 immune response; recent
research has shown that genetic polymorphisms in the OPN
gene determine the magnitude of the immune reaction, and
SNPs in the promoter region of human OPN may affect the
necroinflammatory activity in chronic hepatitis C patients
(CHC) (5).
The mechanisms by which HCV interferes with IFN
signaling and attenuates antiviral efficacy are not fully
elucidated. HCV infection leads to endogenous IFN produc-
tion and increased expression of the suppressor of cytokine
signaling 3 (SOCS3) via viral core proteins or IFN inhibitory
factors (6). SOCS3 can suppress JAK-STAT signaling at the
level of STAT1 (Signal Transducer and Activator of
Transcription 1) phosphorylation by blocking the IFN-
induced formation of interferon-stimulated gene factor 3
(ISGF3) (7). Previous studies have reported that an SNP
(-4874nt A.G) in the promoter region of the SOCS3 gene is
associated with a poorer treatment outcome (8).
IL28A, IL28B and IL29 are cytokines related to the lambda
interferon family and have been structurally associated with
the IL-10 family (9). SNPs located upstream of the IL28B
gene are the most important genetic markers for predicting
the response to combination therapy with pegylated IFN-a
and ribavirin in HCV genotype 1 patients (10-12).
IFN-a acts through the well-characterized JAK-STAT
pathway to up- or downregulate hundreds of genes that
function in the immune response pathways (13). SNPs in the
interferon-a pathway genes and interferon-induced genes
within the MxA and OPN (4,14-16) promoter regions are
associated with therapeutic outcome. High intrahepatic
expression levels of interferon-stimulated genes are asso-
ciated with lower antiviral response rates to interferon plus
ribavirin in chronic hepatitis C patients (17).
The aim of this study was to evaluate the influence of host
genetic heterogeneity mediated by SNPs in the promoter
regions of MxA, OPN and SOCS3 in chronic hepatitis C
patients treated with pegylated interferon (Peg-IFN) plus
ribavirin combination therapy. The capacity of these
protective genotypes to predict therapeutic response in
HCV patients was compared with therapeutic response
prediction using IL28B genotypes.
& MATERIALS AND METHODS
Study design and patients
Between January 2010 and March 2011, 181 adult out-
patient clinic patients chronically infected with HCV
genotype 1 who were treated with a combination of Peg-
IFN alpha-2a or alpha-2b and ribavirin were consecutively
screened. Of these patients, 143 were treated for the first
time, whereas 38 had been previously treated with a
combination of standard alpha-2a or alpha-2b interferon
and ribavirin.
Inclusion criteria
We included viral genotype 1 CHC patients who were
older than 18 years old and were treated with Peg-IFN
alpha-2a or alpha-2b plus ribavirin.
Exclusion criteria
The exclusion criteria were hepatitis B or HIV co-infection
and alcohol intake $40 g of ethanol/day or other con-
comitant chronic liver disease.
The patients were divided into the following 2 groups: the
SVR (sustained virologic response) group (individuals who
had achieved SVR), and the non-response (NR) group
(individuals who were non-responders or relapsers to
therapy). Other data were obtained from patient interviews
and chart reviews. SVR was defined as undetectable HCV
RNA in serum 24 weeks after the end of therapy. Patients
received 48 weeks of treatment. Non-response to therapy
was defined as an HCV viral load decline of less than 2 logs
at week 12 during therapy or detectable serum HCV RNA at
any time during therapy up to 48 weeks. Relapse was
defined as undetectable HCV RNA in serum at the end of
therapy followed by detectable HCV RNA after disconti-
nuation of therapy.
Genotyping of allelic variants
Genomic DNA from the peripheral blood mononuclear
cells was isolated using the DNA Blood MiniKit (Invitrogen,
USA). We defined protective genotypes as those genotypes
associated with a sustained virological response.
MxA
The biallelic polymorphism in the promoter region of
MxA rs2071430 at position -88nt (G.T) and rs17000900 at
position -123nt (C.A) from the transcription start site was
determined by PCR-restriction fragment length polymorph-
ism (RFLP), as described by Hijikata et al. (4). Amplification
was conducted using Taq DNA Polymerase High Fidelity
(Invitrogen, USA).
OPN
The SNPs in the OPN promoter region at position -616nt
(rs2853744; G.T) and position -449nt (rs11730582; T.C) were
analyzed by the direct sequencing of DNA fragments (5). The
extracted genomic DNA was amplified using Taq DNA
Polymerase High Fidelity (Invitrogen, USA). The direct
sequencing was performed using BigDye Terminator v3.1
Ready Reaction Cycle Sequencing (Applied BioSystems, USA).
SOCS3 and IL28B
The SOCS3 and IL28B SNPs were genotyped by real-time
PCR. Thermal cycling was performed on a Step One Real-
Time PCR System (Applied BioSystems, USA). The fluores-
cence data were collected, and the genotypes were
determined using Sequence Detection Systems software
version 1.3.1 (Applied BioSystems). The genotyping of the
SOCS3 promoter region at -4874nt (of rs4969170 A.G) was
performed according to Persico et al. (8). The SNP for IL28B
was rs12979860 (T.C).
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Ancestry informative markers (AIMs)
Genetic ancestries were determined by analyzing the
ancestry informative markers (AIMs) for African,
Amerindian and European populations. The allele*1 was
defined as the presence of insertion or the lack of restriction
enzyme site (18). The AIMs were selected based on previous
studies that analyzed a panel of 48 ancestry markers in
different populations (18-20). Seven AIMs were selected that
had higher than 48% ethno-geographical differential fre-
quencies for Amerindian/European, African/European and
Amerindian/African ancestries.
The evaluated AIMs were as follows: African ancestry, AT3-
I/D (rs3138521) and LPL (rs285); European ancestry, Sb19.3
(rs3138524), APO (rs3138522) and FY-Null (rs2814778); and
Amerindian ancestry, PV92 (rs3138523) and CKMM (rs4884).
Three SNPs (FY-null, LPL and CKMM) were determined
using the Taqman assay (Applied BioSystems, USA); 3 Alu
insertion polymorphisms (APO, Sb19.3 and PV92) and a
polymorphic insertion of a 68-bp fragment at locus AT3-I/D
were analyzed for specific alleles using PCR (19-21).
Statistical analysis
The statistical analysis was performed using the R projects
software version 2.11.1 for Windows (http://www.r-project).
The categorical data were analyzed using Fisher’s exact tests
or the x2 test; the continuous data were analyzed using the
non-parametric Mann-Whitney U test. The univariate factors
with p-values less than 0.05 and confidence intervals of 95%
were considered to be statistically significant.
The allele frequencies were estimated by the gene
counting method using the GENEPOP online version
4.0.10 (http://genepop.curtin.edu.au) (22). The admixture
proportions of each population sample were estimated by
the ADMIX software version 2.0 software [www.genetica.
fmed.edu.uy] (23,24). The parental population allele fre-
quencies used were described by Shriver et al. (18).
Ethics
This study was approved by the ethics committee of the
institution, and all of the patients provided written informed
consent. All of the procedures were in accordance with the
ethical standards of the responsible committee on human
experimentation and with the Helsinki Declaration of 1975 as
revised in 1983.
& RESULTS
Of the 181 HCV individuals in the study, 52 achieved
SVR, and 129 were non-responders/relapsers to the
combined Peg-INF alpha-2a or alpha-2b and ribavirin
therapy. The patient characteristics are described in
Table 1. Severe fibrosis (Metavir F3 and F4) was observed
more frequently in those patients who did not respond to
the combination treatment (OR = 2.27; 95% CI: 1.11–4.65;
p= 0.018) when compared to the sustained responders.
Our studied population was admixed, and the genetic
ancestry analysis revealed a tri-hybrid population with the
following genetic ancestry contribution: African, 43.6%;
European, 31.9% and Amerindian, 24.6%. We found that
patients in the NR/R group had a higher contribution of
African ancestry (46.6%) compared to European (27.2%) and
Amerindian (26.1%) ancestries, whereas the patients in the
SVR group had a greater contribution of European ancestry
(40.4%) compared to African (35.6%) and Amerindian (24%)
ancestries (p= 0.048).
Polymorphisms in the MxA promoter
Linkage disequilibrium was observed between the MxA
SNPs rs2071430 and rs17000900 (p = 0.001).
The polymorphisms in MxA at position -88 (rs2071430)
were associated with patient response to Peg-INF and
ribavirin therapy (Table 2). The G/G was significantly less
frequent in the SVR group than in the NR/R group (11.2 vs.
88.8%, p,0.0001). G/T heterozygosis plus T/T homozygosis
was present in 54% of the patients who achieved SVR and in
46% of the subjects from the NR/R group. The T allele had a
significantly higher frequency in the patients with SVR
(OR = 0.39; 95% CI: 0.21–0.71; p= 0.003).
The SNP at position -123 (rs17000900) was associated with
a therapeutic response. As shown in Table 2, non-respon-
ders/relapsers had a higher frequency of C/C homozygotes
than did the sustained virological responders (82.6% vs.
17.4%, p,0.0001), which is similar to the frequency of G/G
homozygotes for rs2071430.
Polymorphisms in the OPN promoter
The direct sequencing of the DNA fragments between nt -
733 and -236 in 181 patients revealed 2 SNPs in the promoter
region of OPN, located at nt -616 (rs2853744) and -443
(rs11730582). The prevalence of these 2 SNPs is shown in
Table 2. The T/T genotype for the SNP at rs2853744 was
associated with a sustained virological response to
antiviral Peg-IFN-a therapy (60% vs. 40%, p = 0.013). The
T allele occurred more frequently in the SVR group
compared to the NR/R group (OR = 0.30; 95% CI: 0.12 -
0.73; p = 0.009).
Patients with the T/T genotype for the SNP at rs11730582
(64.3%) had a significantly higher SVR rate than patients
Table 1 - Comparison of the baseline characteristics of individuals infected with HCV by response to Peg-IFN-a/ RBV
therapy.
N SVR N=52 (%) NR N=129 (%) OR (95% CI) p-value
Gender
Female 62 13 (21) 49 (79) 1.83 (0.89-3.78) 0.066
Male 119 39 (32.8) 80 (67.2)
Age (years) ¡ SD 181 50¡9.6 53¡10.1 0.149
Liver fibrosis stage
#F2 78 28 (63.6) 50 (43.5) 2.27 (1.11–4.65) 0.018
F3/F4 81 16 (36.4) 65 (56.5)
ALT (U/L) 166 117.42 113.08 0.733
Viral Load (IU/ml) 73 5.6 5.9 0.270
SD= standard deviation; OR=odds ratio; 95% CI = 95% confidence interval.
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with the T/C or C/C genotypes (12.8%). T/C + C/C was
associated with non-response/relapse (12.8% vs. 87.2%,
p,0.0001). The T allele had a strong association with the
SVR rate (OR = 0.23; 95% CI: 0.12 - 0.43; p= 0.001). No
linkage disequilibrium was noted between the SNPs.
Polymorphisms in the SOCS3 promoter
Our data show that the SNP located at nt -4874
(rs4969170) in the promoter region of the SOCS3 gene is
associated with the antiviral treatment response. As shown
in Table 2, the A/G + A/A genotype was more frequent
among the subjects in the NR/R group compared to the SVR
group (79.9% vs. 20.1%, p,0.0001). The G/G genotype
frequency was much higher in the SVR patients than in the
NR/R patients (62.2% vs. 37.8%, p,0.0001).
The alleles were not associated with the antiviral therapy
response (OR = 0.56; 95% CI: 0.32 – 1.00; p= 0.065).
Analysis of the combination of protective
genotypes at the MxA, OPN and SOCS3 promoter
regions
A higher number of protective genotypes present in a
patient indicated a higher probability of achieving sustained
virological response (Figure 1). The patients who had 3 or
more protective genotypes had a greater than 90% prob-
ability of attaining SVR (OR = 0.01; 95% CI: 0.001 - 0.10;
p,0.0001). There were few patients with higher numbers of
protective genotypes.
Polymorphisms in the IL28B gene
Individuals with the C allele in the IL28B polymorphism at
rs12979860 had a greater probability of achieving SVR,
whereas patients with the T allele had a greater probability
of non-response (OR = 0.45; 95% CI: 0.25–0.80; p= 0.009). The
C/C genotype was more frequent in the SVR group, whereas
Table 2 - MxA, OPN, SOCS3 and IL28B polymorphism genotype and allele frequencies by therapeutic outcome in
patients with chronic hepatitis C.
SVR N=52 (%) NR N=129 (%) OR (95% CI) p-value
MxA (rs2071430)
Genotypes
G/G 12 (11.2) 95 (88.8) 0.10 (0.05-0.22) ,0.0001
G/T + T/T 40 (54) 34 (46)
Allele frequency




C/C 20 (17.4) 95 (82.6) 0.22 (0.11-0.44) ,0.0001
C/A + A/A 32 (48.5) 34 (51.5)
Allele frequency




T/T 9 (60) 6 (40) 0.23 (0.07-0.69) 0.013
G/T + G/G 43 (25.9) 123 (74.1)
Allele frequency




T/T 36 (64.3) 20 (35.7) 0.08 (0.03-0.17) ,0.0001
T/C + C/C 16 (12.8) 109 (87.2)
Allele frequency




G/G 23 (62.2) 14 (37.8) 0.15 (0.07-0.33) ,0.0001
A/G + A/A 29 (20.1) 115 (79.9)
Allele frequency




C/C 20 (58.8) 14 (41.2) 0.20 (0.09–0.47) 0.0008
C/T + T/T 24 (22.9) 81 (77.1)
Allele frequency
C 0.648 0.458 0.45 (0.25–0.80) 0.009
T 0.352 0.542
OR=odds ratio; 95% CI = 95% confidence interval.
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the C/T and T/T genotypes were more frequent in the NR/R
group (OR = 0.20; 95% CI: 0.09–0.47; p= 0.0008) (Table 2).
Polymorphisms in the MxA, OPN and SOCS3
promoter genes and prediction of therapy response
when analyzed in combination with IL28B gene
The comparisons of the separate analysis of each
protective genotype in the OPN and SOCS3 genes to the
IL28B C/C genotype (rs12979860) detected an association
between SVR and those polymorphisms. The protective
genotypes from MxA were not associated with SVR
compared to IL28B.
The combined analysis of the MxA, OPN and SOCS3
genotypes with IL28B C/C revealed that patients with 3 or
more protective genotypes had a greater probability of
attaining SVR compared to patients with only the IL28B C/
C genotype (OR = 0.07; 95% CI: 0.02 - 0.20; p,0.0001)
(Figure 1).
In this population, analysis of only the isolated protective
IL28B genotype (C/C) was associated with SVR in 58.8% of
patients. Analyzing the IL28B C/C with the protective OPN
genotype (T/T) at rs11730582 increased the SVR proportion
to 85.7% (OR = 0.23; 95% CI: 0.11-0.46; p,0.0001). The
combination of the IL28B C/C with the SOCS3 protective
genotype (G/G) achieved a predictive SVR rate of 91.7%
(OR = 0.12; 95% CI: 0.05-0.28; p,0.0001) (Figure 2).
For the 181 patients who were treated for chronic HCV,
the frequencies of the protective genotypes were 30.9%
for OPN T/T (rs11730582), 20.4% for SOCS3 G/G and 18.8%
for IL28B C/C. The frequencies of the combinations of
protective genotypes were 6.6% for the IL28B C/C plus
OPN T/T and 6.07% for the IL28B C/C plus SOCS3 G/G.
& DISCUSSION
SNPs may be associated with the therapeutic outcome of
treatment with Peg-INF and ribavirin, and IL28B genotypes
have been reported to be significant markers in recent trials
(10). In this study, we found that the combined presence of
more than 3 protective genotypes from the OPN, MxA and
SOCS3 genes was as effective at predicting the therapeutic
response as was CC IL28B alone. We verified that grouping
the SOCS3 and IL28B protective genotypes increased the
capacity to predict SVR.
Interferons exert their biological effects primarily through
the JAK-STAT pathway, which regulates gene transcription
and mediates antiproliferative, antiviral and immunomo-
dulatory responses (25). SOCS3 interacts with the JAKs,
resulting in impaired STAT1 and STAT3 phosphorylation,
reduced levels of STAT1, impaired binding to the inter-
feron-sensitive response element (ISRE) and decreased
interferon-stimulated gene (ISG) expression (26). Persico
et al. (8) reported that the SOCS3 rs4969170 A/A genotype
was strongly associated with a failure to respond to HCV
antiviral therapy. In our study, the G/G genotype was more
frequently found in the sustained virological responders,
whereas the A/G + A/A genotype was most frequent in
NR/R subjects. Persico et al. (8) found that the A/A
genotype carriers had significantly higher SOCS3 mRNA
and protein expression levels, suggesting that high SOCS3
expression in the liver, as observed in the non-responders,
may be associated with non-response to HCV therapy (27).
The SOCS3 rs4969170 A.G polymorphism is located within
the binding region for 2 transcription factors, RUNX1 and
PURa. The allelic G form binds both factors, whereas the
allelic A form only binds RUNX1 (28). The SOCS3 A allele
could predispose patients to overproducing SOCS3 and to
resistance to antiviral therapy (29). The MxA and OPN
proteins could be downregulated by SOCS3 overexpression,
suppressing IFN-a-induced STAT activation and the expres-
sion of antiviral proteins.
The SNPs in OPN may be crucial in stimulating diverse
Th1 immune responses to HCV by regulating OPN
expression in the liver. The Th1 response is involved in
inflammation in chronic hepatitis C; HCV-infected hepato-
cytes are eradicated by the Th1 response during IFN-based
Figure 1 - Analysis of combinations of MxA, OPN and SOCS3 protective genotypes compared with IL28B by therapeutic response.
Patients who had 3 or more protective genotypes had a greater than 90% probability of attaining SVR.
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therapies. The T/T genotype in the OPN polymorphism at
rs11730582 was significantly associated with SVR, whereas
the T allele was less frequently found in the NR/R group;
this observation is in agreement with the data from Naito et
al. (16). The SVR group had a higher frequency of the T/T
genotype at the OPN SNP rs2853744, although this finding
was not confirmed by other authors (5,16). OPN SNPs may
affect OPN expression in the liver because they are located
just upstream of the cis-acting enhancing element of human
OPN (29).
We evaluated the MxA gene at rs17000900 and noted
linkage disequilibrium with rs2071430. Therefore, only
rs2071430 was analyzed. The G/T and T/T genotypes were
present more frequently in the SVR patients, whereas the
G/G genotype was associated with NR/R, suggesting that
the T allele has a protective effect. This assertion is
supported by an in vitro study that reported higher
transcriptional activity when stimulated by interferon-alpha
and by the fact that the T allele polymorphism at rs2071430
increases the homology of its encompassing sequence
element to an ISRE (4). Patients with the G/G genotype
may produce a suboptimal MxA response from treatment
with interferon-alpha. Our data agree with the findings that
indicated a statistical association between heterozygosis and
SVR.
We detected a lower frequency of the C/C genotype
(18.8%) in the IL28B polymorphisms (rs12979860) than did a
previous study (35%) (10), possibly because of the high
African contribution in our admixed population. In separate
analyses of the 143 naı¨ve patients and the 38 previous NR/
Rs to standard interferon-based therapy patients who were
retreated with Peg-INF plus ribavirin, the results remained
identical for all of the analyzed SNPs (data not shown),
indicating that the low frequency of C/C IL28B may be a
result of the high African contribution in our population
(30). In our study population, the C/C genotype frequency
was highly associated with the SVR group (58.8%), which is
in agreement with the literature; Ge et al. found that the
protective IL28B genotype is associated with SVR in
approximately 55% of African Americans (10).
The MxA, OPN and SOCS3 protective genotypes exhib-
ited individual associations with the therapeutic response;
when analyzed together, the power to predict an SVR
response increased progressively. The SVR response rate
was 93.3% in patients with combinations of MxA, OPN and
SOCS3 protective genotypes, whereas 58.8% of patients with
the C/C IL28B genotype experienced SVR. The frequency of
the combined MxA, OPN and SOCS3 protective genotypes
in our study population was 10%.
We evaluated the combination of the MxA, OPN and
SOCS3 protector genotypes with C/C IL28B to increase the
probability of predicting the therapeutic response but found
significant associations only with the OPN and SOCS3
genes. The frequency of SVR for the OPN and IL28B (T/T +
C/C) combination of protective genotypes was 85.7%. The
combined genotypes were present at a frequency of 6.6%,
whereas the individual genotype frequencies were 30.9%
(T/T OPN) and 18.8% (C/C IL28B).
The frequency of SVR for the SOCS3 and IL28B (G/G +
C/C) combination of protective genotypes was 91.7%,
which is higher than the individual frequencies of G/G
SOCS3 (62.2%) and C/C IL28B (58.8%). The combined
genotype (G/G + C/C) frequency was 6.07%, which is lower
than the individual G/G SOCS3 (20.4%) and C/C IL28B
(18.8%) frequencies. Although the frequency of the com-
bined protective genotypes is low, its predictive power is
reasonably accurate and is superior to the predictive power
of C/C IL28B alone. A plausible biological explanation for
this finding is that a less active SOCS3 allows IFN-lambda
and IFN-alpha to signal more effectively via the JAK-STAT
pathway to transcribe anti-viral proteins.
Figure 2 - Prediction of therapeutic response based on the combined analysis of protective OPN (rs11730582) or SOCS3 genotypes
with the protective IL28B genotype. The protective IL28B genotype (C/C) alone was associated with SVR in 58.8% of the patients. The
IL28B C/C genotype combined with the protective OPN genotype (T/T) at rs11730582 increased the SVR proportion to 85.7%. The
combination of IL28B C/C with the SOCS3 protective genotype (G/G) achieved a predictive SVR rate of 91.7%.
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A previous study of HCV genotype 1 patients examined
the effect of the IL28B genotype; ancestry analysis indicated
that patients with the C/C genotype had an SVR rate
of approximately 80% (10). Self-classified European-
Americans had an SVR rate slightly higher than 80%. The
authors explained that European ancestry is associated with
a higher frequency of the IL28B C allele, which results in a
greater probability of SVR. In our study, the group with a
combination of the C/C IL28B and G/G SOCS3 genotypes
had a greater SVR rate than the group with only the C/C
IL28B genotype. Our results suggest that the association
between the protective genotypes G/G SOCS3 and C/C
IL28B is a more powerful predictor of SVR.
Our study population was admixed; the genetic ancestry
analysis revealed a tri-hybrid population. It appears that our
study population is more ethnically heterogeneous than
populations evaluated in European and North American
studies. We found that the patients in the NR/R group had
a higher contribution of African ancestry, whereas the
patients in the SVR group had a greater European
contribution.
In conclusion, the combination of the MxA, OPN and
SOCS3 protective genotypes was more frequent among the
SVR patients. The combined analysis of the SOCS3 and
IL28B protective genotypes (G/G + C/C) had greater power
than IL28B to predict SVR. The limitations of the study must
be clarified. Our study population was relatively small, and
most of the combinations of SNPs that predicted treatment
outcomes more effectively than did the IL28B genotype
alone were present in less than 10% of the patients. New
studies involving combination polymorphism analysis
should be encouraged to validate our findings.
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